LM N°1/ 2024. OVERVIEW OF REGENLAB'S PATENTED TECHNOLOGIES. Andreas PIGNI. Legal Affairs, RegenLab SA.
OVERVIEW OF REGENLAB'S PATENTED TECHNOLOGIES Andreas PIGNI Legal Affairs, RegenLab SA INTRODUCTION RegenLab SA has established itself as a pioneer and leader in regenerative medicine, known for its innovative technologies that synergistically use platelet-rich plasma (PRP) in combination with various bioactive/therapeutic agents, thus providing solutions to [...].
LM N°1/ 2024. PLATELET-RICH PLASMA (PRP) AS AN ALTERNATIVE TO FETAL CALF SERUM (FBS) IN THE EXPANSION OF HUMAN MYOBLASTS: AN IN VITRO PROTOCOL. Axel TOLLANCE, Diego MICHEL, Alexandre PROLA, Axelle BOUCHE, Antoine TURZI, Didier HANNOUCHE, Thomas LAUMONIER and Sarah BERNDT
Muscular diseases, whether congenital, acquired or degenerative, are a major cause of death.
major challenge for public health, affecting patients' quality of life and often leading to
significant morbidity. Muscle regeneration is a complex process involving the
participation of various cell populations, notably muscle stem cells (MSCs),
which play a central role in restoring muscle integrity and function after
lesions [1, 2]. However, in pathological conditions such as muscular dystrophy of
Duchenne muscular dystrophy (DMD), muscle regeneration capacities are compromised, highlighting
the need to develop new therapeutic approaches to treat these diseases
debilitating muscular problems.
LM N°1/ 2024. ANGIOGENESIS, A KEY STEP IN TISSUE REGENERATION, IS MODULATED BY PLATELETS. Sarah BERNDT PhD, Gilles CARPENTIER, Axel TOLLANCE PhD, Antoine TURZI.
All you need to know. Another look ANGIOGENESIS, A KEY STEP IN TISSUE REGENERATION, IS MODULATED BY PLAQUES. Sarah BERNDT PhD1, Gilles CARPENTIER2, Axel TOLLANCE PhD1,3, Antoine TURZI1 1 Regen Lab SA, 1052 Le Mont-sur-Lausanne, Switzerland. 2 Gly-CRRET Research Unit 4397, Université Paris-Est Créteil, Créteil, France. 3 Department of Orthopedic Surgery, Geneva [...]
LM N°1/ 2024. REGENPRP®, A STANDARDIZED AUTOLOGOUS PLATELET CONCENTRATE. 10 YEARS OF RESEARCH AND PRACTICE. Pr Barbara Hersant Editor-in-Chief, L&M
Platelet Rich Plasma (PRP) has emerged as an innovative therapeutic modality in the
various medical fields, offering promising prospects for wound healing, the
facial rejuvenation and even genital rejuvenation.
Our clinical research is resolutely committed to studying these applications, seeking to determine
the efficacy and safety of RegenPRP® (standardized PRP prepared with RegenLab SA technology),
Switzerland) in these varied clinical contexts.
This technology makes it possible to obtain liquid RegenPRP, in the form of autologous fibrin sealant or fibrin glue.
combined with hyaluronic acid (Cellular Matrix® technology) to meet different needs
therapeutics.
-
In the field of wound healing, RegenPRP is attracting growing interest due to the following factors
its regenerative properties and its potential to accelerate the healing process. Our
research aims to deepen our understanding of how RegenPRP can optimize the
healing of post-operative and traumatic wounds, improving clinical outcomes for patients and their families.
patients.
-
Facial rejuvenation is one area where RegenPRP has become an increasingly popular option.
increasingly popular. By harnessing the cell regeneration capabilities of RegenPRP, our study
examines how this therapy can be used safely and effectively to alleviate the signs of aging.
of skin ageing, offering a non-surgical alternative to traditional
facial rejuvenation.
-
In a revolutionary way, our research also explores the possibilities of rejuvenation.
using RegenPRP. This innovative approach aims to restore function and appearance
of the genitalia, offering a new means of treatment for patients suffering from
sexual dysfunction and aesthetic problems in this region.
It should be noted that all our studies are conducted in compliance with the most stringent standards in the field.
ethics and regulations. Approved by the French medical agency and supervised by a
independent ethics committee, our prospective studies guarantee the scientific rigor and safety of our products.
participants.
Our clinical research on RegenPRP is opening up exciting new perspectives in the fields of
wound healing, facial rejuvenation and genital rejuvenation through the combination of a
rigorous scientific approach with a commitment to medical innovation. We aim to improve
clinical results and patients' quality of life thanks to this promising therapy.
Key words: RegenPRP®, Cellular Matrix®, combination of RegenPRP® and hyaluronic acid, surgery
plastic, skin grafting, vulvovaginal atrophy, keloid scars, mesenchymal stromal cells.
LM N°1/ 2024. Autologous PRP or "The Fairy Plate" in the magical land of regenerative autologous cellular medicine. Antoine TURZI. CEO of RegenLab
Platelet Rich Plasma (PRP) has emerged as an innovative therapeutic modality in a variety of medical fields, offering promising prospects for wound healing, facial rejuvenation and even genital rejuvenation.
Our clinical research is resolutely committed to studying these applications, seeking to determine the efficacy and safety of RegenPRP® (standardized PRP prepared with technology from RegenLab SA, Switzerland) in these varied clinical contexts.
LM N°1 /2024 THE RISE OF PLATELET-RICH PLASMA (PRP) IN REGENERATIVE MEDICINE: A PROMISING HORIZON. Prof. Jean-Paul MENINGAUD, Scientific Director, L&M.
Editorial 1 THE IMPROVEMENT OF PLATE-RICH PLASMA (PRP) IN REGENERATIVE MEDICINE: A PROMISING HORIZON. Prof. Jean-Paul MENINGAUD Head of the Plastic, Reconstructive and Maxillofacial Surgery Department. Hôpital Henri Mondor, Créteil, France. Scientific Director of "Look et Medecine". President of the "AIME" Congress. Regenerative medicine, in its perpetual quest for progress and innovation, has recently been enriched by a promising approach: the use of platelet-rich plasma (PRP). This [...]
LM N°1/ 2024. Look & Medicine interviews. The promises of "the Fairy platelet" for autologous regenerative cell therapy. The promises of "the Fairy platelet" for autologous regenerative cell therapy. Antoine TURZI, CEO of RegenLab. Interview by Pr Albert Claude BENHAMOU, Past President of the French National Academy of Surgery.
plaquetas sanguíneas". Las promesas del " Hada de las plaquetas " para la terapia celular regenerativa autóloga. plaquetas sanguíneas ". Las promesas del " Hada de las plaquetas " para la terapia celular regenerativa autóloga. plaquetas sanguíneas ". Las promesas del " Hada de las plaquetas " para la terapia celular regenerativa autóloga. plaquetas sanguíneas ". Las promesas del "Hada de las plaquetas" para [...].
LM N°1/ 2024. Look & Medicine interviews. The promises of "the Fairy platelet" for autologous regenerative cell therapy. The promises of "the Fairy platelet" for autologous regenerative cell therapy. Antoine TURZI, CEO of RegenLab. Interview with Pr Albert Claude BENHAMOU, Past President of the French National Academy of Surgery. Interviews with "L&M".
LES PROMESSES DE " LA FÉE PLAQUETTE " POUR LA MÉDÉCINE RÉGNÉRATIVE CELLULAIRE AUTOLOGUE THE PROMISES OF " THE PLATELET FAIRY " FOR AUTOLOGOUS REGENERATIVE CELL THERAPY. LAS PROMESAS " DEL HADA PLAQUETA " PARA LA TERAPIA CELULAR REGENERATIVA AUTOLOGA. Antoine TURZI, CEO of RegenLab